![Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire](https://mms.businesswire.com/media/20210107005469/en/739014/5/teva_RGB_JPEG.jpg)
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
![Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021 Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021](https://pharma.nridigital.com/pharma/pharma_feb21/teva_medincell_lai_schizophrenia/1118760/__screenshot.jpg)
Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021
![Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study - ScienceDirect Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0920996421004515-gr1.jpg)
Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study - ScienceDirect
![Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market - Clinical Trials Arena Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market - Clinical Trials Arena](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/11/Glenmark-1038x778.jpg)
Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market - Clinical Trials Arena
![PDF) A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP) | abraham nussbaum and M. PDF) A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP) | abraham nussbaum and M.](https://0.academia-photos.com/attachment_thumbnails/35501918/mini_magick20190314-21389-1n2isxh.png?1552554786)
PDF) A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP) | abraham nussbaum and M.
![Influence of Aripiprazole, Risperidone, and Amisulpride on Sensory and Sensorimotor Gating in Healthy 'Low and High Gating' Humans and Relation to Psychometry | Neuropsychopharmacology Influence of Aripiprazole, Risperidone, and Amisulpride on Sensory and Sensorimotor Gating in Healthy 'Low and High Gating' Humans and Relation to Psychometry | Neuropsychopharmacology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnpp.2014.102/MediaObjects/41386_2014_Article_BFnpp2014102_Fig1_HTML.jpg)
Influence of Aripiprazole, Risperidone, and Amisulpride on Sensory and Sensorimotor Gating in Healthy 'Low and High Gating' Humans and Relation to Psychometry | Neuropsychopharmacology
![Sezepine Forte Risperidone Trihexyphenidyl Tablets, Vega Biotec Pvt Ltd, 5x4x10, Rs 1120 /box | ID: 23427778548 Sezepine Forte Risperidone Trihexyphenidyl Tablets, Vega Biotec Pvt Ltd, 5x4x10, Rs 1120 /box | ID: 23427778548](https://5.imimg.com/data5/SELLER/Default/2021/5/JG/WQ/HR/3184985/sezepineforte-500x500.jpg)
Sezepine Forte Risperidone Trihexyphenidyl Tablets, Vega Biotec Pvt Ltd, 5x4x10, Rs 1120 /box | ID: 23427778548
![Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire](https://mms.businesswire.com/media/20210107005469/en/739014/22/teva_RGB_JPEG.jpg)